PMID- 17541176
OWN - NLM
STAT- MEDLINE
DCOM- 20070717
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 30
IP  - 6
DP  - 2007 Jun
TI  - Relationship between amount of drug delivered to lungs and amount released from 
      Diskhaler by inhalation with tapping.
PG  - 1167-70
AB  - It is well known that drug residue remains in a fluticasone propionate Diskhaler 
      (FP-DH) following a single inhalation. Thus, the inspiratory ability of the 
      patient has an influence on the effects of the drug. In a previous study, we 
      reported that the amount of drug remaining in an FP-DH was decreased by tapping 
      the device after the first inhalation. In the present study, we investigated the 
      relationship between the amount of drug delivered to the lungs and amount of drug 
      released from the FP-DH by inhalation along with tapping using an in vitro model. 
      We measured the amounts delivered to the throat, stage 1, and stage 2 of a twin 
      impinger device by HPLC-UV, following inhalation and tapping of 100 microg of 
      FP-DH at various inspiratory flow rates, which ranged from 11.5 to 73.6 l/min for 
      2 s. A positive linear correlation between the amount of drug released from the 
      FP-DH and that deposited in stage 2 was observed. Amounts deposited in stage 2 
      following tapping were estimated to be 6.0 microg at an inspiratory flow rate of 
      20 l/min and 10.6 microg at 60 l/min, while those without tapping were 2.0 microg 
      and 10.2 microg, respectively. Notably, at an inspiratory flow rate of 20 l/min, 
      the amount of drug deposited in stage 2 by tapping was increased about 3-fold in 
      comparison to that without tapping. Our results indicate that the amount of drug 
      deposited in stage 2, i.e., the lung in our model, is increased by tapping of the 
      device, which would be particularly helpful for patients with a lower level of 
      inspiratory ability.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
AD  - School of Pharmacy, Tokyo University of Pharmacy and Life Science, Japan.
FAU - Yamamura, Yoshikazu
AU  - Yamamura Y
FAU - Abe, Toshihide
AU  - Abe T
FAU - Ohkawa, Sunao
AU  - Ohkawa S
FAU - Ozeki, Takeshi
AU  - Ozeki T
FAU - Iga, Tatsuji
AU  - Iga T
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Androstadienes)
RN  - 0 (Bronchodilator Agents)
RN  - CUT2W21N7U (Fluticasone)
SB  - IM
MH  - Administration, Inhalation
MH  - Androstadienes/administration & dosage
MH  - Bronchodilator Agents/administration & dosage
MH  - Fluticasone
MH  - Humans
MH  - *Inhalation
MH  - Inspiratory Capacity
MH  - Lung/*physiology
MH  - *Metered Dose Inhalers
MH  - Models, Biological
MH  - Time Factors
EDAT- 2007/06/02 09:00
MHDA- 2007/07/18 09:00
CRDT- 2007/06/02 09:00
PHST- 2007/06/02 09:00 [pubmed]
PHST- 2007/07/18 09:00 [medline]
PHST- 2007/06/02 09:00 [entrez]
AID - JST.JSTAGE/bpb/30.1167 [pii]
AID - 10.1248/bpb.30.1167 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2007 Jun;30(6):1167-70. doi: 10.1248/bpb.30.1167.